ArticleFrontiers in microbiology2026
Global resurgence of norovirus GII.17[P17] accompanies shifting phylogeographic connectivity patterns: surveillance in Jiangsu, 2023-2025.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Norovirus GII.17[P17] has re-emerged and has been circulating globally since 2023. In Jiangsu, China, we found that its proportion increased from 2024 onward. Using local surveillance data combined with global sequences, we reconstructed the global spatiotemporal dynamics of GII.17[P17] and explored its evolution and molecular mechanisms. Methods: Samples were subjected to whole-genome sequencing using next-generation sequencing. We used bioinformatics tools to analyze the full viral protein 1 sequences for molecular evolution, spatiotemporal phylogeographic associations, and amino acid changes. Results: From October 2024 to May 2025, 209 GII.17[P17] outbreaks were reported (approximately 26 per month), while only 23 outbreaks occurred in the full year of 2023 (fewer than 2 per month). In sporadic case surveillance, the proportion of GII.17[P17] increased from 9.6% in 2023 to 62.4% in January-May 2025. The maximum clade credibility tree showed that GII.17[P17] clustered into two large clusters. Most samples from 2024 to 2025 belonged to Lineage 3 of Cluster II. In the phylogenetic network and minimum spanning tree, we identified three core hub strains. Inferred phylogeographic connectivity patterns suggest a shift in the primary centers of viral lineage dispersal from East Asia (Cluster I, 2014-2016) to Northwest Europe (Cluster II, 2021-2025). Molecular evolutionary analysis revealed that the current dominant lineage (Lineage 3, Cluster II) exhibited an evolutionary rate of 4.126 × 10 Conclusion: Inferred phylogeographic connectivity patterns indicate that the primary centers of GII.17[P17] lineage dispersal have shifted from East Asia (2014-2016) to Northwest Europe (2021-2025). The current dominant lineage (Lineage 3, Cluster II) exhibits an accelerated evolutionary rate, approximately 2.3-fold faster than Cluster I lineages, and carries lineage-specific amino acid substitutions in antigenic epitopes temporally associated with its global expansion. These findings highlight the value of sustained genomic surveillance in regions with high inferred phylogeographic connectivity for monitoring norovirus evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.